Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Thermo Fisher sepsis test focus of Fujirebio license agreement
January 2013
SHARING OPTIONS:

WALTHAM, Mass.Thermo Fisher Scientific Inc. and Fujirebio Diagnostics Inc. have inked a long-term license agreement to make Thermo Fisher Scientific's test for the early detection of sepsis available on the latter's laboratory instruments, namely its Lumipulse product line. The sepsis test, the PCT assay, is available worldwide on laboratory instruments from a range of strategic license partners. Financial details and additional terms were not disclosed.

"This agreement with Fujirebio ensures that PCT testing will be available to a much broader patient base, helping to improve patients' outcome," Marc Tremblay, president of Thermo Fisher Scientific's Clinical Diagnostics business, said in a press release. "Through the earlier detection of sepsis, healthcare providers can offer much better treatment to their patients and also achieve dramatic cost savings."

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.